Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: Role of peroxisome proliferator-activated receptor-γ

Circulation

Volumn 105, Issue 19, 2002, Pages 2296-2302

  Diep, Quy N ^a   Mabrouk, Mohammed E ^a   Cohn, Jeffrey S ^a   Endemann, Dierk ^a   Amiri, Farhad ^a   Virdis, Agostino ^a   Neves, Mario Fritsch ^a   Schiffrin, Ernesto L ^a  

^a CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

Author keywords

Arteries; Hypertension; Inflammation; Muscle, smooth; Remodeling

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANGIOTENSIN; CELL ADHESION MOLECULE; CELL CYCLE PROTEIN; CYCLIN D1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PIOGLITAZONE; ROSIGLITAZONE; VASCULAR ADHESION PROTEIN 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE REGULATION; BLOOD VESSEL; CELL GROWTH; CONTROLLED STUDY; ENDOTHELIUM CELL; HEART VENTRICLE REMODELING; INFLAMMATION; INSULIN RESISTANCE; LIPID METABOLISM; MACROPHAGE ACTIVATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR UPREGULATION; SMOOTH MUSCLE CONTRACTION; VASCULAR SMOOTH MUSCLE;

ALDOSTERONE; ANGIOTENSIN II; ANIMALS; ANTIGENS, CD31; BLOOD PRESSURE; BLOOD VESSELS; BODY WEIGHT; CELL CYCLE PROTEINS; CELL DIVISION; COLLAGEN; DNA; DRUG ADMINISTRATION SCHEDULE; ENDOTHELIUM, VASCULAR; INFLAMMATION; INJECTIONS, SUBCUTANEOUS; LIPIDS; MALE; NF-KAPPA B; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ANGIOTENSIN; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RENIN; THIAZOLES; THIAZOLIDINEDIONES; TRANSCRIPTION FACTORS; VASCULAR CELL ADHESION MOLECULE-1; VASOCONSTRICTOR AGENTS; VASODILATOR AGENTS;

EID: 0037076294     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000016049.86468.23     Document Type: Article

References (35)

1. Essential hypertension, part I: Definition and etiology
2. An antidiabetic thiazolidinedione is a high affinity ligand for PPAR-γ
3. The retinoid X receptor enhances the function of the PPAR
4. PPAR-γ activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPAR-γ as a potential mediator in vascular disease
5. PPAR-γ activators inhibit gene expression and migration in human vascular smooth muscle cells
6. Macrophages in human atheroma contain PPAR-γ: Differentiation-dependent PPAR-γ expression and reduction of MMP-9 activity through PPAR-γ activation in mononuclear phagocytes in vitro
7. Angiotensin II causes vascular hypertrophy in part by a non-pressor mechanism
8. Vascular remodeling in hypertension: Roles of apoptosis, inflammation and fibrosis
9. The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats
10. Blood pressure lowering by pioglitazone: Evidence for a direct vascular effect
11. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan
12. Expression of cell cycle proteins in blood vessels of angiotensin II-infused rats: Role of AT(1) receptors
13. Effect of bosentan on NF-kappaB, inflammation, and tissue factor in angiotensin II-induced end-organ damage
14. Vascular angiotensin II receptors in renal and DOCA-salt hypertensive rats
15. Peroxisome proliferator-activated receptor gamma activators downregulate angiotensin II type 1 receptor in vascular smooth muscle cells
16. Transcriptional suppression of type 1 angiotensin II receptor gene expression by PPAR-γ in vascular smooth muscle cells
17. Differential effects among thiazohdinediones on the transcription of thromboxane receptor and angiotensin II type 1 receptor genes
18. Troglitazone inhibits angiotensin II-induced DNA synthesis and migration in vascular smooth muscle cells
19. PPAR-γ ligands inhibit retinoblastoma phosphorylation and GI→S transition in vascular smooth muscle cells
20. p38 MAP kinase regulates vascular smooth muscle cell collagen synthesis by angiotensin II in SHR but not in WKY
21. Vascular remodeling
22. Effects of antihypertensive therapy on hypertensive vascular disease
23. PPAR-γ agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats
24. The effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man
25. Effects of insulin on renal haemodynamics and the proximal and distal tubular sodium handling in healthy subjects
26. PPARs: Novel therapeutic targets in renal disease
27. Increased expression of PPAR-α and -γ in blood vessels of spontaneously hypertensive rats
28. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells
29. Superoxide production, risk factors, and endothelium-dependent relaxations in human internal mammary arteries
30. The PPAR-γ is a negative regulator of macrophage activation
31. PPARs inhibit thromb-ininduced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway
32. PPAR activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction
33. PPAR-γ ligands inhibit migration mediated by multiple chemoattractants in vascular smooth muscle cells
34. PPAR-γ dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation
35. Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension